Cover Image
市場調查報告書

Zensun (Shanghai) Sci & Tech Co., Ltd.的產品平台分析

Zensun (Shanghai) Sci & Tech Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 271852
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Zensun (Shanghai) Sci & Tech Co., Ltd.的產品平台分析 Zensun (Shanghai) Sci & Tech Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 31 Pages
簡介

Zensun (Shanghai) Sci & Tech Co., Ltd.是總公司設立於中國的生物製藥企業,以生命攸關的心臟疾病及腫瘤為對象,正在研究開發抗癌藥·小分子藥·抗體藥等生技藥品。

本報告提供Zensun (Shanghai) Sci & Tech Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Zensun (Shanghai) Sci & Tech Co., Ltd.的基本資料

  • Zensun (Shanghai) Sci & Tech Co., Ltd.概要
  • 主要資訊
  • 企業資料

Zensun (Shanghai) Sci & Tech Co., Ltd.:R&D概要

  • 主要的治療範圍

Zensun (Shanghai) Sci & Tech Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Zensun (Shanghai) Sci & Tech Co., Ltd.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Zensun (Shanghai) Sci & Tech Co., Ltd.:藥物簡介

  • Neucardin
  • rhErbB3-f
  • ZS-05
  • ZS-03
  • ZS-04

Zensun (Shanghai) Sci & Tech Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Zensun (Shanghai) Sci & Tech Co., Ltd.:最新的開發平台資訊

Zensun (Shanghai) Sci & Tech Co., Ltd.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07571CDB

Summary

Global Markets Direct's, 'Zensun (Shanghai) Sci & Tech Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Zensun (Shanghai) Sci & Tech Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zensun (Shanghai) Sci & Tech Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zensun (Shanghai) Sci & Tech Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zensun (Shanghai) Sci & Tech Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zensun (Shanghai) Sci & Tech Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Zensun (Shanghai) Sci & Tech Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zensun (Shanghai) Sci & Tech Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zensun (Shanghai) Sci & Tech Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zensun (Shanghai) Sci & Tech Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zensun (Shanghai) Sci & Tech Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zensun (Shanghai) Sci & Tech Co., Ltd. Snapshot
    • Zensun (Shanghai) Sci & Tech Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products Glance
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Drug Profiles
    • Neucardin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rhErbB3-f
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-07
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-08
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Analysis
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Target
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Route of Administration
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Molecule Type
    • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Mechanism of Action
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Recent Pipeline Updates
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zensun (Shanghai) Sci & Tech Co., Ltd., Key Information
  • Zensun (Shanghai) Sci & Tech Co., Ltd., Key Facts
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Indication, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Stage of Development, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Phase III, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Phase II, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Phase I, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Preclinical, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Target, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Route of Administration, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Molecule Type, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Recent Pipeline Updates, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd., Subsidiaries

List of Figures

  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Stage of Development, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Zensun (Shanghai) Sci & Tech Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top